Turnover September 30, 2025 | Revenue Report

Sophie BoissardCEO of the Clariane Group, declared:
“Clariane is once again recording good momentum across all of its networks and activities this quarter, supported by solid underlying quality and by the strong investment of its teams, whom I would like to thank. The growth in turnover benefits on the one hand from the regular increase in occupancy rates in the Nursing Homes and Shared Habitats activity as well as, on the other hand, from the continuous improvement of the case mix and volumes, particularly ambulatory, in the Specialized Health activities. While the Group was able to finalize its plan to strengthen its financial structure in good conditions in the first half of the year, we are making improving our operating margin our priority more than ever, while respecting our commitments and our mission. The actions undertaken in France and Germany to adjust the Group’s central and operational organization to the post-divestiture scope and to the new market and regulatory conditions, particularly in the SMR, are producing their first effects in the second half of 2025, with an expected acceleration in 2026, in accordance with the roadmap that we have set for ourselves. »

Warning

This document contains information of a forward-looking nature which is associated with risks and uncertainties, including information included or incorporated by reference, concerning the growth and profitability of the Group in the future which may imply that the expected results differ materially from those indicated in the information of a forward-looking nature. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking information contained in this document constitutes anticipations of a future situation and must be considered as such. The sequence of events or actual results may differ from those described in this document due to a certain number of risks and uncertainties described in Chapter 2 of the 2024 Universal Registration Document filed with the AMF on March 31, 2025 under registration number D.25-0209, available on the Company’s website (www.clariane.com) and that of the AMF (All forward-looking statements included in this document are valid only as of the date of this press release. Clariane SE makes no commitment and assumes no liability with regard to updating the information contained in this document beyond what is prescribed by the regulations in force.
The reader should not place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accept responsibility for the reasonableness of the assumptions or opinions expressed or the likelihood of the projections, prospects or returns being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be considered as, a promise or statement for the future. Furthermore, no statement contained herein is intended to be or may be construed as a prediction of results. Clariane’s past performance cannot be considered a guide to future performance.
In this press release, and unless otherwise indicated, all variations are expressed on an annual basis (2025/2024), and at constant scope and exchange rates.
The main alternative performance indicators (IAP), such as the notions of “EBITDA”, “EBIT”, “net debt” or even “financial leverage”, are the subject of a definition accessible in the Universal Registration Document available on the company’s website www.clariane.com.

As of September 30, 2025, the consolidated turnover of the Group is established at €3 976mi.e. growth of +1.1% on a reported basis and +4.9% on an organic basis. The difference between published and organic performance is explained by the impact of disposals occurring in 2024 and 2025 as part of the plan to strengthen the Group’s financial structure, restated for revenue from real estate development and the review of expected revenues under the reform of healthcare activities in France.
This dynamic confirms the solidity of the group which relies on a diversified portfolio, both in terms of activities and geographies.
On the 3th quarter 2025the turnover stands at €1 320mup +1.8% on a reported basis and +5.1% on an organic basis.

The network operated as of September 30, 2025all activities combined, now counts 1,233 establishmentscompared to 1,216 as of September 30, 2024, for a total of more than 90 000 unitsstable compared to the same date in 2024. These developments take into account:

These operations were partially offset by:

In total, between September 2024 and September 2025, the Group sold or closed 24 establishments, while at the same time commissioning 41 modern establishments.

Revenue growth of +4.9% on an organic basis results from:

The turnover progressing in France +3.4% on an organic basis over the entire period. The contraction on a published basis is explained by the impact of the various disposals that have taken place since 2024 as part of the plan to strengthen the financial structure, and in particular of Petits-fils on July 30, 2025.

The turnover in Germany is clearly improving as of September 30, 2025, supported by the regular increase in the volume of activity and the continuation of price catch-up.

Growth remains strong in the region, with turnover up +5.1% on an organic basis as of September 30, 2025.

In Belgium, turnover for September 30, 2025 amounted to €502m, up +3.9% on an organic basis.

In the Netherlands, turnover as of September 30, 2025 stood at €126m, up +10.1% on an organic basis.

The Italian market remained well oriented over the first nine months of the year, with turnover increasing by +2.4% on an organic basis. The slight contraction observed on a reported basis of -1.2% results from disposals occurring as part of the plan to strengthen the Group’s financial structure.

* Taking into account the finalization of the sale of all of the Group’s activities in the United Kingdom on 04/09/2024, the Group’s performance therefore includes the financial performance achieved in the United Kingdom over the entire first quarter of 2024.

The activity in the United Kingdom has been fully deconsolidated since April 9, 2024. As a reminder, turnover in the United Kingdom amounted to €17m as of April 9, 2024, the date of the sale of all of the Group’s assets and activities in this country.

Turnover in Spain amounts to €197m as of September 30, 2025, an increase of +6.4% on an organic basis (+6.8% on a reported basis).

The Nursing Homes activity, which represents 63.6% of the Group’s activity, generated revenue of €2 527m as of September 30, 2025, up +3.1% on a reported basis and +4.7% on an organic basis.
This growth on an organic basis is based both on the continued progression in the volume of activity, reflected by the increase in the occupancy rate which reached 90,8% on average as of September 30, 2025 compared to 90.2% over the same period in 2024, and on an increase in prices.
It should be noted that on the third quarter 2025the turnover stands at €848mup +1.9% on a reported basis and +3,3% on an organic basis. The occupancy rate is improving, standing at 91,6% compared to 90.7% in the third quarter of 2024.

During the first nine months of 2025, the Health Establishments and Services activity generated revenue of €963mor 24.2% of the group’s turnover, down -3.0% on a reported basis, taking into account the sale of home hospitalization activities in 2024 and the corrections made to certain allocations in France in the first half.
On an organic basis, it is growing by +3.2% over the first nine months of the year and +6.7% over the third quarter.

The turnover of the Home and shared housing activity amounts to €486m as of September 30, 2025, representing 12.2% of the Group’s turnover, an increase of +9.4% on an organic basis. Taking into account the sale of Petits-fils on July 30 and certain small sales in Germany and Italy, activity fell by -1.0% on a reported basis.
It should be noted that on the third quarter 2025the turnover stands at €155mup +1.3% on a reported basis and +11,7% on an organic basis.

In 2025the main objective of the Group was to finalize its plan to strengthen the financial structure and to regain normalized access to financing, which was achieved 6 months in advance.

From the point of view of its operational performance and as indicated during the publication of its results as of June 30, 2025, the Group will benefit in the second half of the year:

It will also benefit from first effects of adjustment and savings measures on its central and operational organizations, following the disposal program, and to adapt, particularly in France, to the new regulatory framework and the more uncertain market environment. These measures are gradually ramping up and will have their full effects in the 2026 financial year..

In this context, Clariane :

About 2026the favorable trajectory of operational improvement expected in the second half of 2025 should continue. The Group is thus aiming for an objective improvement in its EBITDA margin pre-IFRS 16pro forma and excluding real estate, 100 to 150 basis points compared to 2023.

The Group also confirms its objective of reducing its “Wholeco” financial leverage at one level less than 5x as of December 31, 2026.

As part of the publication of its turnover as of September 30, 2025, Clariane will hold an online information meeting, in English, on October 28, 2025 at 3:00 p.m. (CET).

Connection :

The presentation which will support this event will be accessible on the Clariane company website www.clariane.com from 12:00 p.m. (CET).

About Clariane

Clariane is the first European community of care in moments of fragility. It is present in six countries: Germany, Belgium, Spain, France, Italy and the Netherlands.
With their different expertise, the Group’s 63,000 employees work each year to serve nearly 900,000 people supported and cared for in three major areas of activity: nursing homes (Korian, Seniors Residencias, etc.), specialized health establishments and services (Inicea, Ita, Grupo 5, etc.) as well as shared homes and habitats (Ages & Vie, etc.).
In June 2023, Clariane became a mission-driven company and included in its statutes a new purpose, common to all its activities: “Taking care of everyone’s humanity in moments of fragility”.

The Clariane group has been listed on Euronext Paris, Section B, since November 2006. The Group joined the SBF 120 index as well as the CAC® SBT 1.5° index on September 23, 2024.

Euronext ticker: CLARI.PA – ISIN: FR0010386334

Stéphane Bisseuil Benoit Lesieur
Director of Investor Relations Deputy Director of Investor Relations – ESG
+33 6 58 60 68 69                                                        +33 6 64 80 15 90
stephane.bisseuil@clariane.com                                benoit.lesieur@clariane.com

Julie Mary Florian Bachelet
Press relations manager Press relations manager
06 59 72 50 69                                                                06 79 86 78 23
julie.mary@clariane.com                                florian.bachelet@clariane.com

Attachment

CP_Clariane – Turnover as of September 30, 2025_VF_SC